Primary Care Diabetes
Volume 3, Issue 4 , Pages 211-217 , November 2009

Identification of persons with dysglycemia: Terminology and practical significance

  • David F. Williamson

      Affiliations

    • Corresponding Author InformationCorresponding author at: Hubert Department of Global Health, Rollins School of Public Health, Emory University, 1518 Clifton Rd N.E., Room 740, Atlanta, GA 30322, USA. Tel.: +1 770 488 1054; fax: +1 770 488 8211.
    • ,
  • K.M. Venkat Narayan

Received 30 March 2009 ,Revised 18 August 2009 ,Accepted 25 August 2009.

References 

  1. Wilson JMG. Principles of screening for disease. Proc. R. Soc. Med. 1971;64:39–40
  2. Cole P, Morrison AS. Basic issues in population screening for cancer. J. Nat. Cancer Inst. 1980;64(5):1263–1272
  3. Cadman D, et al. Assessing the effectiveness of community screening programs. JAMA. 1984;251:1580–1585
  4. Miller AB. Principles of screening and of the evaluation of screening programs. In:  Miller AB editors. Screening for Cancer. New York: Academic Press; 1985;p. 3–24
  5. J. Elavunkal, et al., Screening and Diagnostic Tests Emedicine from WebbMD, Accessed 4/23/08. http://www.emedicine.com/emerg/TOPIC779.HTM.
  6. Engelgau MM, Narayan KMV, Herman WH. Screening for type 2 diabetes. Diabet. Care. 2000;23:1563–1580
  7. Waugh NSG, McNamee P, et al. Screening for type 2 diabetes: literature review and economic modeling. Health Technol. Assess. 2007;11(7):144
  8. Lauritzen T, et al. The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screening. Int. J. Obes. Relat. Metab. Disord. 2000;24(Suppl. 3):S6–11
  9. Gulliford MC, Latinovic R, Charlton J. Diabetes diagnosis, resource utilization, and health outcomes. Am. J. Manag. Care. 2008;14:32–38
  10. Ackermann RT, et al. An evaluation of cost sharing to finance a diet and physical activity intervention to prevent diabetes. Diabet. Care. 2006;29:1351–1356
  11. Coughlin SS. Ethical issues in epidemiologic research and public health practice. Emerg. Themes Epidemiol. 2006;3:10
  12. Berwick D, et al. Refining and implementing the Tavistock principles for everybody in health care. BMJ. 2001;323:616–620
  13. Park P, et al. Screening for type 2 diabetes is feasible, acceptable, but associated with increased short-term anxiety: a randomised controlled trial in British general practice. BMC Public Health. 2008;8:1–9
  14. Havas S. The ACCORD trial and control of blood glucose level in type 2 diabetes mellitus: time to challenge conventional wisdom. Arch. Int. Med. 2009;169:150–154
  15. The Diabetes Prevention Program Research Group . Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New Engl. J. Med. 2002;346:393–403
  16. National Institute for Health and Clinical Excellence (NICE). August 17, 2009; Available from: http://www.nice.org.uk/.
  17. Commission on Chronic Illness . Chronic Illness in the United States, Prevention of Chronic Illness, vol. 1. Cambridge, Massachusetts: Harvard University Press; 1957;p. 45
  18. Wormald R. Epidemiology in practice: screening for eye disease. Commun. Eye Health. 1999;12:29–30
  19. American Diabetes Association . Standards of medical care in diabetes—2009. Diabet. Care. 2009;32(Suppl. 1):S14
  20. Evans P, Langley P, Gray DP. Diagnosing type 2 diabetes before patients complain of diabetic symptoms—clinical opportunistic screening in a single general practice. Fam. Pract. 2008;25:376–381
  21. National Health Service, NHS Health Check [August 17, 2009], Available from: http://www.nhs.uk/Planners/NHSHealthCheck/Pages/NHSHealthCheck.aspx.
  22. Hersberger KE, et al. Sequential screening for diabetes-evaluation of a campaign in Swiss community pharmacies. Pharm. World Sci. 2006;28:171–179
  23. Lindstrom J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabet. Care. 2003;26:725–731
  24. American Diabetes Association . Screening for type 2 diabetes. Diabet. Care. 2004;27(Suppl. 1):S11–S14
  25. Greaves CJ, et al. A simple pragmatic system for detecting new cases of type 2 diabetes and impaired fasting glycaemia. Fam. Pract. 2004;21:57–62
  26. Sellers EAS, Dean HJ. Screening for type 2 diabetes in a high-risk pediatric population: capillary vs. venous fasting plasma glucose. Can. J. Diabet. 2005;29:393–396
  27. Kruijshoop M, Feskens EJ, Blaak EE, et al. Validation of capillary glucose measurements to detect glucose intolerance or type 2 diabetes mellitus in the general population. Clin. Chem. Acta. 2004;341:33–40
  28. Ziemer DC, et al. Age, BMI, and race are less important than random plasma glucose in identifying risk of glucose intolerance. Diabet. Care. 2008;31:884–886
  29. World Health Organization, Screening for Type 2 Diabetes. Report of a World Health Organization and International Diabetes Federation meeting WHO/NMH/MNC/03.1. Geneva, 2003: p. 1–48.
  30. Balion CM, et al. Reproducibility of impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) classification: a systematic review. Clin. Chem. Lab. Med. 2007;45:1180–1185
  31. The International Expert Committee . International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. Diabet. Care. 2009;32:
  32. Sackett DL, et al. Evidence based Medicine: How to Treat and Practice Evidence Based Medicine. Edinburgh: Churchill; 1997;
  33. Saaristo T, et al. Cross-sectional evaluation of the Finnish diabetes risk score: a tool to identify undetected type 2 diabetes, abnormal glucose tolerance and metabolic syndrome. Diabet. Vasc. Dis. Res. 2005;2:67–72

PII: S1751-9918(09)00086-2

doi: 10.1016/j.pcd.2009.08.006

Primary Care Diabetes
Volume 3, Issue 4 , Pages 211-217 , November 2009

Article Tools